Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.
Igor Puzanov
No relevant relationships to disclose
Jeffrey Alan Sosman
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
Robert E. Martell
No relevant relationships to disclose
Grace K. Dy
No relevant relationships to disclose
Laura Williams Goff
No relevant relationships to disclose
Wen Wee Ma
No relevant relationships to disclose
Gerald J. Fetterly
No relevant relationships to disclose
Shaunita A. Michael
No relevant relationships to disclose
Julie Ann Means-Powell
No relevant relationships to disclose
Feng Chai
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
Maria Lamar
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
Gary M. Strauss
No relevant relationships to disclose
Paolo A. Zucali
No relevant relationships to disclose
Wendy M. Chiang
No relevant relationships to disclose
Jamie Jarboe
Research Funding - Genentech
Brian E. Schwartz
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
Alex A. Adjei
Honoraria - Daiichi Sankyo
Research Funding - Ardea Biosciences; Bayer; Pfizer; Syndax